Literature DB >> 9252146

Intrahepatic cholestasis of pregnancy: a French prospective study.

Y Bacq1, T Sapey, M C Bréchot, F Pierre, A Fignon, F Dubois.   

Abstract

The aim of this prospective study was to analyze the characteristics of intrahepatic cholestasis of pregnancy (ICP) in a French population. From 1989 to 1995 we studied 50 consecutive pregnant women with ICP (41 single, 7 twin, and 2 triplet pregnancies) referred for hepatologic consultation. All patients suffered from pruritus and/or jaundice associated with elevated fasting serum levels of total bile acids (mean 49 micromol/L, range 7-290). No patients had concomitant liver disease and all recovered normal liver function after delivery. Overall prematurity rate was 60%: 100% in multiple pregnancies and 41% in single pregnancies. Three of 61 babies died. Systematic clinical interviews revealed that 34 patients had been treated with oral micronized natural progesterone (200-1,000 mg/d) during the current pregnancy for risk of premature delivery, including at least 32 (64%) before the onset of pruritus. Onset of pruritus was statistically earlier in patients previously receiving progesterone than in patients not receiving progesterone (217 +/- 21 vs. 240 +/- 26 days, P < .01). This was also found in the single pregnancy subgroup of patients (222 +/- 19 vs. 240 +/- 26 days, P < .05). Pruritus disappeared before delivery in 10 of 50 patients, i.e., after withdrawal of progesterone in 7 patients (only one concurrently treated with cholestyramine), after decrease in dose of progesterone in 1 patient, and spontaneously in 2 patients. During the same period, the percentage of pregnant women without ICP who had been treated with progesterone during pregnancy was statistically lower than the percentage of patients treated with progesterone before the onset of pruritus in our group of patients with ICP (36% vs. 64%, P < .01, odds ratio 3.16, 95% CI:1.29-7.80). These results suggest that orally administered progesterone might be an exogenous factor which triggers ICP in predisposed women.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252146     DOI: 10.1002/hep.510260216

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites.

Authors:  Shadi Abu-Hayyeh; Pablo Martinez-Becerra; Siti H Sheikh Abdul Kadir; Clare Selden; Marta R Romero; Myrddin Rees; Hanns-Ulrich Marschall; Jose J G Marin; Catherine Williamson
Journal:  J Biol Chem       Date:  2010-02-20       Impact factor: 5.157

Review 2.  Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems.

Authors:  Jurate Kondrackiene; Limas Kupcinskas
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

Review 3.  Intrahepatic cholestasis of pregnancy.

Authors:  Victoria Geenes; Catherine Williamson
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

4.  Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene.

Authors:  H E Wasmuth; A Glantz; H Keppeler; E Simon; C Bartz; W Rath; L-A Mattsson; H-U Marschall; F Lammert
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

5.  The angiotensin-converting enzyme gene insertion-deletion polymorphism in a white British patient cohort with obstetric cholestasis.

Authors:  Roman Müllenbach; Natasha Tetlow; Amanda Bennett; Fiona Broughton Pipkin; Linda Morgan; Catherine Williamson
Journal:  Obstet Med       Date:  2009-05-22

Review 6.  Immunology of hepatic diseases during pregnancy.

Authors:  Lars Bremer; Christoph Schramm; Gisa Tiegs
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

7.  Intrahepatic Cholestasis of Pregnancy.

Authors:  Frank Lammert; Hanns-Ulrich Marschall; Siegfried Matern
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 8.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 9.  Liver diseases in pregnancy: diseases unique to pregnancy.

Authors:  Khulood T Ahmed; Ashraf A Almashhrawi; Rubayat N Rahman; Ghassan M Hammoud; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Intrahepatic cholestasis of pregnancy: biochemical predictors of adverse perinatal outcomes.

Authors:  Hui Chen; Yuan Zhou; Dong-Rui Deng; Hai-Yan Hao; Jing Dang; Jing Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.